PGNY vs CVS

For growth investors, Progyny, Inc.

(PGNY) is the stronger pick with 10. 4% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Progyny, Inc. (PGNY) offers the better valuation at 29. 5x trailing P/E (16. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Progyny, Inc.

(PGNY) is the cheapest at 29. 5x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.

0%, compared to -62. 9% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: PGNY returned +20. 2% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Progyny, Inc. 's 0. 71β — meaning PGNY is approximately 1301% more volatile than CVS relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Progyny, Inc.

(PGNY) is pulling ahead at 10. 4% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Progyny, Inc. grew EPS 14. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 2. 6% for CVS. At the gross margin level — before operating expenses — PGNY leads at 23. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 16. 4x for Progyny, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

In this comparison, CVS (3.

1% yield) pays a dividend. PGNY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, PGNY: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PGNY is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while PGNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.